Sanofi cell-based flu vaccine enters clinic
This article was originally published in Pharmaceutical Approvals Monthly
Sanofi-Aventis' vaccines division has initiated the first clinical trial of its cell culture-based influenza vaccine. The 100-person U.S. trial is part of a contract awarded by HHS to accelerate development of a new cell culture-based influenza vaccine, Sanofi noted. Novartis is another firm with a cell-based flu vaccine in development; the firm acquired the vaccine through its purchase of Chiron...
You may also be interested in...
The US FDA and NIST have agreed to help industry modernize and update pharmaceutical manufacturing methods and to improve supply chain resilience.
Medtronic is sponsoring a trial to evaluate its adaptive deep brain stimulation technology, a unique feature of the Percept PC device for treating Parkinson’s disease.
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.